recent
identif
novel
human
coronaviru
respons
sarslik
ill
middleeast
decad
sar
pandem
demonstr
reemerg
sarslik
coronaviru
anim
reservoir
remain
credibl
threat
sar
contract
aerosol
contamin
respiratori
tract
vaccin
induc
mucos
longterm
protect
would
asset
control
new
epidem
aim
gener
live
attenu
recombin
measl
vaccin
mv
candid
express
either
membraneanchor
sarscov
spike
protein
secret
solubl
ectodomain
ssol
mice
suscept
measl
viru
recombin
mv
express
anchor
fulllength
induc
highest
titer
neutral
antibodi
fulli
protect
immun
anim
intranas
infecti
challeng
sarscov
compar
immun
adjuv
recombin
ssol
protein
recombin
mv
induc
stronger
respons
hallmark
live
attenu
virus
highli
desir
featur
antivir
vaccin
sever
acut
respiratori
syndrom
sar
newli
emerg
human
infecti
diseas
first
appear
china
late
novemb
juli
viru
spread
differ
countri
contin
respons
clinic
case
lead
death
case
manag
guidelin
restrict
travel
advic
allow
bring
sar
control
juli
etiolog
agent
sar
identifi
novel
coronaviru
name
sarsassoci
coronaviru
sarscov
ksiazek
et
al
genet
distinct
previous
character
member
coronavirida
famili
outbreak
sarscov
isol
chines
civet
racoon
dog
guan
et
al
viru
like
introduc
human
popul
kan
et
al
song
et
al
sarscovlik
virus
share
nucleotid
ident
sarscov
isol
chines
horsesho
bat
therefor
propos
repres
natur
reservoir
host
sarscov
date
endem
bat
sarscovlik
virus
also
detect
africa
europ
review
balboni
et
al
reemerg
sarslik
diseas
anim
reservoir
remain
credibl
public
health
threat
effici
vaccin
would
effect
way
control
new
epidem
similar
coronavirus
sarscov
envelop
positivestrand
rna
viru
whose
replic
take
place
cytoplasm
infect
cell
viral
particl
compos
four
major
structur
protein
nucleoprotein
n
small
envelop
protein
e
membran
protein
larg
spike
protein
spike
protein
typei
transmembran
glycoprotein
amino
acid
assembl
homotrim
surfac
viral
particl
give
virion
crownlik
appear
neuman
et
al
monom
kda
compos
signal
sequenc
aa
larg
ectodomain
aa
potenti
nglycosyl
site
transmembran
domain
aa
short
cytoplasm
tail
aa
content
list
avail
sciencedirect
journal
homepag
wwwelseviercomlocateyviro
rota
et
al
protein
respons
viral
entri
bind
cellular
receptor
mediat
fusion
viral
cellular
membran
petit
et
al
simmon
et
al
structur
ntermin
globular
head
domain
aa
contain
receptorbind
region
wong
et
al
membraneanchor
stalk
region
domain
aa
mediat
oligomer
fusion
petit
et
al
similarli
coronavirus
cleavag
protein
proteas
subunit
requir
activ
membran
fusion
domain
follow
bind
target
cell
receptor
matsuyama
et
al
simmon
et
al
due
critic
involv
receptor
recognit
well
viru
attach
entri
protein
promis
studi
candid
antigen
sarscov
vaccin
develop
major
target
neutral
antibodi
human
patient
nie
et
al
anim
model
buchholz
et
al
tripp
et
al
passiv
transfer
igg
convalesc
sar
patient
enhanc
recoveri
acut
phase
patient
administ
within
day
onset
symptom
yeh
et
al
administr
sspecif
antibodi
includ
monoclon
antibodi
anim
confer
protect
subsequ
sarscov
infect
demonstr
antibodi
alon
protect
sar
mice
bisht
et
al
hamster
robert
et
al
ferret
ter
meulen
et
al
rhesu
macaqu
miyoshiakiyama
et
al
accordingli
sever
candid
vaccin
reli
induct
spikespecif
neutral
antibodi
includ
dna
vaccin
callendret
et
al
yang
et
al
live
viral
vector
buchholz
et
al
chen
et
al
kapadia
et
al
live
attenu
vaccin
subunit
vaccin
bisht
et
al
et
al
zhou
et
al
inactiv
viru
vaccin
stadler
et
al
zhou
et
al
report
induc
protect
immun
respons
variou
anim
model
evalu
phase
clinic
trial
lack
natur
challeng
data
efficaci
human
roper
rehm
ideal
vaccin
sar
induc
longlast
protect
respons
singl
administr
produc
low
cost
scale
million
dose
live
attenu
vaccin
particularli
appropri
mass
vaccin
inexpens
manufactur
induc
strong
immun
longterm
memori
singl
inject
evalu
vaccin
approach
previous
develop
vector
deriv
liveattenu
schwarz
strain
measl
viru
mv
combredet
et
al
mv
vaccin
liveattenu
negativestrand
rna
viru
proven
one
safest
effect
human
vaccin
produc
larg
scale
mani
countri
distribut
low
cost
extend
program
immun
epi
vaccin
induc
lifelong
immun
measl
one
two
inject
previous
show
mv
vector
stabli
express
differ
protein
hiv
flavivirus
induc
strong
longterm
transgenespecif
neutral
antibodi
cellular
immun
respons
even
presenc
preexist
immun
mv
brandler
et
al
brandler
et
al
despr
et
al
guerboi
et
al
lorin
et
al
present
studi
evalu
immunogen
potenti
recombin
mvsar
vector
express
either
fulllength
secret
ectodomain
spike
glycoprotein
sarscov
mous
model
mv
infect
mvsar
recombin
virus
induc
neutral
antibodi
sarscov
fulli
protect
immun
anim
intranas
challeng
sarscov
antibodi
respons
induc
mvsar
vector
quantit
qualit
compar
respons
induc
prototyp
subunit
vaccin
prepar
alumadjuv
recombin
ssol
protein
synthes
human
codonoptim
gene
encod
fulllength
membran
anchor
sarscov
spike
protein
entir
ectodomain
residu
hereaft
design
ssol
express
mammalian
cell
solubl
secret
polypeptid
callendret
et
al
callendret
et
al
unpublish
result
length
respect
rule
six
stipul
total
number
nucleotid
mv
genom
must
multipl
calain
roux
mv
editingand
polyadenylationlik
sequenc
mutat
lamb
kolakofski
schneider
et
al
ssol
sequenc
insert
addit
transcript
unit
atu
mv
vector
ptmmvschw
plasmid
contain
infecti
mv
cdna
correspond
antigenom
schwarz
vaccin
strain
combredet
et
al
fig
result
ptmmvschw
ptmmvschwssol
plasmid
transfect
helper
cell
previous
describ
combredet
et
al
correspond
recombin
measl
virus
mv
mvssol
success
rescu
indic
format
syncytia
propag
vero
cell
cultur
analyz
replic
mv
mvssol
virus
vero
cell
use
moi
standard
mv
stock
product
fig
growth
mvssol
slightli
delay
compar
parent
empti
schwarz
mv
mvschwarz
final
yield
routin
obtain
h
postinfect
high
ident
parent
mvschwarz
viral
growth
yield
mv
affect
mvssol
may
due
reduc
mv
bud
insert
full
length
surfac
infect
cell
alreadi
observ
mv
express
membraneanchor
form
lorin
et
al
analyz
express
sarscov
spike
antigen
indirect
immunofluoresc
ifa
vero
cell
infect
recombin
virus
immunoblot
infectedcel
lysat
h
postinfect
ifa
perform
permeabil
cell
use
anti
hyperimmun
mous
ascit
fluid
reveal
strong
express
fulllength
entir
ectodomain
ssol
spike
protein
along
compart
secretori
pathway
measlesinduc
syncytia
fig
upper
panel
infect
cell
permeabil
label
cell
surfac
mv
induc
syncytia
readili
stain
indic
membraneanchor
effici
transport
surfac
fig
lower
panel
western
blot
analysi
cell
lysat
supernat
use
rabbit
anti
polyclon
antibodi
confirm
express
ssol
protein
recombin
mvinfect
vero
cell
expect
appar
molecular
mass
kda
fig
left
panel
reduc
sdspage
condit
full
length
protein
migrat
doublet
describ
two
differenti
glycosyl
form
song
et
al
lighter
product
suggest
erresid
form
glycoprotein
heavier
golgiprocess
form
contain
complex
carbohydr
band
lower
molecular
weight
also
observ
probabl
correspond
minor
degrad
fragment
sinc
present
earlier
time
point
shown
express
level
similar
lysat
mvinfect
veronk
cell
sarscov
infect
cell
expect
fulllength
protein
detect
cell
lysat
contrast
ssol
clearli
detect
lysat
supernat
mvssol
infect
vero
cell
h
infect
fig
right
panel
indic
effici
secret
consist
ssol
protein
secret
cell
cultur
medium
heavier
ssol
observ
within
cell
lysat
agreement
glycoprotein
synthes
immatur
form
er
prior
transfer
golgi
secret
immunogen
recombin
mvschwarzsar
virus
investig
genet
modifi
mice
suscept
mv
infect
mrkic
et
al
compar
immunogen
purifi
ssol
polypeptid
produc
mammalian
cell
constitut
potenti
subunit
vaccin
candid
sar
du
et
al
mice
express
human
receptor
vaccin
mv
strain
lack
receptor
use
previous
model
evalu
immunogen
recombin
mv
brandler
et
al
combredet
et
al
despr
et
al
guerboi
et
al
lorin
et
al
eight
twelveweekold
male
mice
immun
two
intraperiton
ip
inject
interv
tcid
mv
mvssol
recombin
virus
control
group
mice
inject
empti
mv
vector
tcid
anoth
group
mg
purifi
ssol
protein
adjuv
mg
aluminum
hydroxid
alum
usual
dose
small
rodent
mice
sera
collect
three
week
inject
sarscovand
measlesspecif
antibodi
respons
evalu
individu
mous
indirect
elisa
sarscov
mv
nativ
antigen
respect
signific
titer
antisar
igg
rais
mice
first
inject
recombin
mvsar
virus
wherea
preimmun
sera
shown
sera
control
anim
receiv
empti
mvschw
remain
neg
fig
titer
higher
mv
mvssol
inject
anim
averag
titer
log
respect
anim
immun
alumadjuv
ssol
protein
log
titer
po
second
inject
titer
boost
time
anim
immun
mv
vector
talli
result
observ
first
inject
mv
induc
highest
igg
titer
log
p
mvssol
induc
similar
titer
log
alumadjuv
ssol
protein
log
interestingli
antibodi
mv
rais
similar
level
mice
receiv
either
mvschw
mvsar
virus
fig
indic
express
heterolog
protein
recombin
virus
alter
replic
vivo
modifi
measlesspecif
immunogen
addit
qualiti
humor
respons
induc
variou
immunogen
studi
sera
collect
week
second
inject
igg
iga
isotyp
analysi
neutral
assay
first
determin
specif
isotyp
titer
sarscov
antigen
antisar
elisa
fig
immun
alumadjuv
ssol
protein
almost
exclus
induc
indic
induc
immun
respons
predominantli
previous
observ
balbc
mice
callendret
et
al
unpublish
result
contrariwis
mv
mvssol
virus
induc
significantli
higher
titer
antibodi
particularli
mv
averag
ratio
respect
reflect
predomin
immun
respons
induc
live
recombin
measl
vector
interestingli
mvssol
mv
virus
also
induc
moder
log
high
titer
log
antisar
iga
antibodi
respect
fig
wherea
sera
anim
immun
alumadjuv
ssol
protein
remain
neg
log
titero
examin
whether
antibodi
respons
sarscov
neutral
activ
repres
uniqu
correl
protect
immun
sar
robert
et
al
neutral
titer
determin
use
infect
reduct
assay
highest
serum
dilut
suppress
sarscov
cytopath
effect
least
inocul
well
cultur
cell
fig
immun
mvssol
alumadjuv
ssol
protein
induc
compar
level
neutral
antibodi
log
titer
respect
wherea
mv
induc
significantli
threeto
fourfold
higher
neutral
titer
log
titer
p
determin
whether
immun
recombin
mvsar
could
induc
protect
experiment
challeng
mice
inocul
intranas
pfu
sarscov
five
week
second
immun
mice
inocul
empti
mvschw
use
control
evalu
level
protect
viral
replic
quantifi
sarscov
infecti
titer
lung
homogen
prepar
two
day
challeng
fig
control
mice
immun
empti
mvschw
infect
except
one
sarscov
replic
lung
titer
pfulung
show
mice
suscept
intranas
sarscov
infect
agreement
previou
observ
describ
selflimit
bronchiol
mild
moder
pneumon
mice
hogan
et
al
increas
suscept
pathogenesi
histolog
outcom
ifnar
mice
genet
background
frieman
et
al
contrari
mice
immun
mv
fulli
protect
challeng
absenc
sarscov
replic
confirm
quantit
realtim
rtpcr
evidenc
reduct
sarscov
rna
level
lung
mvsimmun
mice
log
detect
level
compar
mvschwimmun
mice
log
geqlung
mice
immun
mvssol
adjuv
ssol
also
protect
albeit
less
effici
one
mous
either
group
low
residu
viral
titer
lung
fig
sarscov
rna
remain
detect
albeit
strongli
reduc
level
lung
half
immun
mice
shown
altogeth
experi
demonstr
recombin
mvsar
virus
express
either
fulllength
secret
ectodomain
spike
protein
induc
neutral
antibodi
sarscov
titer
suffici
protect
anim
experiment
intranas
infect
notic
effici
protect
follow
hierarchi
observ
neutral
antibodi
level
mv
confer
complet
better
protect
viru
replic
mice
lung
mvssol
refer
adjuv
subunit
vaccin
object
studi
evalu
proofofconcept
new
sarscov
vaccin
strategi
base
standard
measl
vaccin
engin
express
sarscov
spike
protein
strategi
might
provid
safe
recombin
vaccin
protect
sarscov
region
might
becom
affect
sarscov
reemerg
due
critic
role
viral
entri
protein
promis
candid
antigen
sarscov
vaccin
develop
robert
et
al
roper
rehm
design
human
codonoptim
gene
encod
fulllength
sarscov
spike
protein
solubl
ectodomain
ssol
sequenc
insert
mv
vector
recombin
virus
produc
revers
genet
grew
standard
titer
express
high
level
sarscov
fulllength
spike
protein
cell
membran
led
effici
secret
solubl
ectodomain
immun
mice
suscept
mv
recombin
mv
mvssol
virus
induc
specif
antibodi
neutral
sarscov
infect
vitro
induct
measlesspecif
immun
alter
express
transgen
immun
prime
sarscovspecif
memori
respons
vigor
boost
second
inject
anchor
fulllength
form
spike
protein
induc
highest
titer
neutral
antibodi
previous
observ
hiv
lorin
et
al
also
robust
respons
prototyp
subunit
vaccin
prepar
adjuv
recombin
ssol
protein
compar
immun
adjuv
ssol
protein
recombin
mvsar
virus
induc
higher
titer
antibodi
indic
bias
respons
hallmark
live
attenu
virus
highli
desir
featur
antivir
vaccin
remark
recombin
mvsar
vector
also
induc
sarscov
specif
iga
wherea
subunit
refer
vaccin
rais
interest
point
sinc
sever
clinic
studi
alreadi
evidenc
parenter
administr
live
attenu
measl
vaccin
children
stimul
secretori
iga
respons
nasal
wash
bellanti
et
al
simon
et
al
although
assess
abil
recombin
mvsar
induc
secretori
iga
lung
upper
respiratori
tract
immun
mice
result
strongli
indic
potenti
mvsar
induc
sarscov
specif
secretori
iga
respons
evalu
efficaci
recombin
mvsar
vector
reli
challeng
wt
human
sarscov
evalu
lung
viru
titer
sinc
unfortun
mouseadapt
sarscov
lethal
mice
frieman
et
al
two
success
immun
recombin
mv
viru
mice
fulli
protect
intranas
infecti
challeng
sarscov
neither
infecti
viru
residu
viral
rna
could
recov
lung
challeng
anim
interestingli
despit
lower
replic
rate
cell
cultur
mv
confer
better
protect
sarscov
replic
mice
lung
mvssol
may
reflect
better
immunogen
nativ
anchoredform
suggest
structur
dissimilar
monomer
solubl
ssol
ectodomain
correspond
membraneassoci
trimer
form
respect
absenc
ineffici
present
antibodi
epitop
truncat
solubl
immunogen
deriv
function
virionassoci
glycoprotein
alreadi
evidenc
filoviru
attach
protein
hiv
davenport
et
al
kovac
et
al
usual
given
intramuscularli
measl
vaccin
protect
effici
measl
diseas
contract
aerosol
contamin
upper
respiratori
tract
similarli
sar
data
demonstr
parenter
immun
mvsar
vector
protect
mice
lung
sarscov
intranas
infect
similar
approach
previous
report
linig
et
al
also
demonstr
induct
neutral
antibodi
mice
sarscov
spike
express
mv
vector
howev
studi
evalu
efficaci
vaccin
prepar
protect
immun
mice
sarscov
challeng
observ
mvsar
induc
strong
respons
appear
particular
import
given
recent
report
safeti
concern
tseng
et
al
describ
lung
immunopatholog
upon
challeng
mice
vaccin
inactiv
whole
viru
sar
vlp
alumadjuv
protein
tseng
et
al
suggest
previous
describ
vaccineinduc
immunopatholog
might
proceed
immunopatholog
promin
eosinophil
infiltr
upon
sarscov
challeng
effect
like
occur
live
vaccin
sinc
induc
potent
respons
agreement
hypothesi
recent
report
live
attenu
sarscov
lack
e
protein
express
provid
longterm
protect
lethal
challeng
agedmic
model
absenc
sign
vaccineinduc
immunopatholog
fett
et
al
live
attenu
rna
viru
vaccin
like
mump
measl
polio
rubella
virus
induc
longterm
cellmedi
humor
immun
one
two
inject
use
mv
vaccin
vector
present
number
advantag
highli
effici
safe
vaccin
easili
produc
larg
scale
vaccin
strain
genet
stabl
mv
recombin
integr
genet
materi
vaccin
persist
diffus
schwarzmoraten
strain
deriv
vector
combredet
et
al
current
attenu
wide
use
measl
vaccin
measl
vector
express
stabli
larg
amount
heterolog
genet
materi
like
due
absenc
geometr
constraint
size
helicoid
nucleocapsid
pleiomorph
viru
tangi
naim
although
stabil
express
specif
sar
transgen
remain
determin
remark
genet
stabil
ad
express
orf
alreadi
describ
us
other
varieti
transgen
insert
measl
vector
member
mononegaviral
measl
vector
demonstr
strong
capac
stimul
cellular
humor
neutral
immun
number
antigen
provid
protect
experiment
challeng
mice
primat
brandler
et
al
brandler
et
al
despr
et
al
lorin
et
al
tangi
naim
measleshiv
vaccin
candid
current
clinic
develop
evalu
phase
clinic
trial
demonstr
gmp
preclin
clinic
safeti
immunogen
vector
steb
et
al
recombin
mv
vaccin
might
use
immun
pediatr
adultadolesc
popul
case
sarscov
outbreak
presenc
antimv
immun
nearli
entir
adult
human
popul
might
restrict
use
recombin
mv
infant
alreadi
worthi
goal
event
howev
numer
studi
shown
revaccin
immun
individu
result
boost
antimv
antibodi
suggest
attenu
live
vaccin
replic
express
protein
spite
preexist
immun
dilraj
et
al
ragerzisman
et
al
sepulvedaamor
et
al
likewis
presenc
matern
antimv
antibodi
shown
limit
induct
antimeasl
antibodi
induct
specif
tcell
respons
infant
given
measl
vaccin
first
year
life
gan
et
al
gan
et
al
moreov
previous
demonstr
recombin
mv
vector
immunogen
induc
protect
presenc
mv
preexist
immun
anim
model
brandler
et
al
lorin
et
al
open
possibl
use
recombin
mv
vector
immun
adolesc
adult
although
point
need
evalu
human
trial
measl
appear
difficult
elimin
still
caus
death
annual
worldwid
mostli
poorli
develop
countri
center
diseas
prevent
europ
also
recent
experienc
sever
measl
outbreak
cottrel
robert
improv
maintain
measl
vaccin
decad
essenti
contain
contagi
diseas
context
use
recombin
mv
design
immun
pediatr
adult
popul
appear
desir
conclus
produc
new
recombin
mvsar
virus
abl
induc
neutral
antibodi
sarscov
full
protect
intranas
challeng
thu
make
proofofconcept
strategi
sar
vaccin
develop
gener
sever
respiratori
infecti
diseas
character
sar
vaccin
candid
deserv
evalu
much
adapt
nonhumanprim
model
crossprotect
potenti
induc
immun
respons
zoonot
sar
isolatesvari
could
address
inde
sever
studi
underlin
need
induc
broadli
neutral
antibodi
abl
protect
heterolog
viral
variant
may
aris
independ
emerg
event
boll
et
al
sheahan
et
al
antigen
variant
alreadi
isol
anim
epidem
sporad
human
case
reemerg
deme
et
al
yang
et
al
like
emerg
larg
heterogen
zoonot
reservoir
sarslik
virus
new
outbreak
occur
recent
identif
novel
human
betacoronaviru
merscov
agent
sarslik
ill
middleeast
rais
great
concern
pandem
potenti
diseas
perlman
zaki
et
al
decad
sar
pandem
renew
worldwid
attent
coronavirus
stress
need
continu
research
invest
develop
safe
effect
vaccin
highli
pathogen
coronavirus
fetal
rhesu
monkey
kidney
veronk
african
green
monkey
kidney
cell
grown
co
complet
dmem
dulbecco
modifi
eagl
medium
mg
ml
lglucos
uml
penicillin
mgml
streptomycin
supplement
heatinactiv
fetal
calf
serum
fc
helper
cell
stabli
express
rna
polymeras
n
p
gene
schwarz
mv
grown
complet
dmem
supplement
fc
sarscov
strain
kindli
provid
dr
hw
doerr
institut
medic
virolog
frankfurt
univers
medic
school
germani
viral
stock
produc
titrat
describ
previous
callendret
et
al
work
involv
infecti
sarscov
perform
enhanc
biosafeti
level
contain
laboratori
rigor
safeti
procedur
accord
guidelin
crude
cell
lysat
prepar
sarscov
infect
cell
inactiv
frozen
gamma
irradi
describ
callendret
et
al
use
sar
nativ
antigen
elisa
solubl
monomer
spike
protein
term
ssol
correspond
entir
ectodomain
residu
fuse
flag
tag
produc
purifi
immunoaffin
chromatographi
sigmaaldrich
supernat
stabl
mammalian
cell
line
callendret
et
al
unpublish
result
human
codonoptim
gene
encod
sarscov
spike
protein
specimen
callendret
et
al
chemic
synthes
geneart
regensburg
germani
subclon
pci
mammalian
express
vector
promega
yield
plasmid
pcissynth
addit
codon
bia
optim
region
high
low
gc
content
avoid
whenev
possibl
furthermor
cisact
sequenc
motif
intern
tatabox
chisit
ribosom
entri
site
in
cr
sequenc
element
well
repetit
sequenc
rna
secondari
structur
splice
donor
acceptor
site
avoid
result
optim
gene
increas
gc
content
sequenc
codonoptim
gene
avail
upon
request
codonoptim
gene
encod
solubl
secret
spike
ectodomain
ssol
obtain
pcr
amplif
use
pcissynth
plasmid
templat
oligonucleotid
actagctagc
ggatccacca
tgttcatctt
contain
restrict
site
underlin
agtatccgga
cttgatgtac
tgctcgtact
contain
restrict
site
pcr
fragment
insert
pcissol
contain
wildtyp
nonoptim
gene
encod
ssol
callendret
et
al
unpublish
data
yield
plasmid
pciscub
measl
recombin
vector
deriv
plasmid
carri
infecti
cdna
correspond
antigenom
schwarz
mv
vaccin
strain
addit
transcript
unit
contain
uniqu
restrict
site
insert
foreign
sequenc
downstream
p
gene
combredet
et
al
fig
fulllength
secret
ssol
spike
sequenc
amplifi
pcr
use
pcissynth
pciscub
plasmid
templat
oligonucleotid
ataggatccc
gtacgaccat
gttcatcttc
contain
bsiwi
restrict
site
underlin
ataggatccg
cgcgcttatc
aggtgtagtg
ataggatccg
cgcgctcatt
atttatcgtc
gtcatcttta
contain
bsshii
restrict
site
underlin
digest
bsiwi
bsshii
restrict
enzym
result
dna
fragment
insert
correspond
site
ptmmvschwegfp
sequenc
insert
mv
vector
respect
rule
six
stipul
number
nucleotid
mv
genom
must
multipl
calain
roux
schneider
et
al
result
plasmid
ptmmvschw
ptmmvschwssol
use
rescu
recombin
virus
use
helpercellbas
system
previous
describ
combredet
et
al
singl
viral
clone
amplifi
veronk
cell
viral
stock
store
titrat
endpoint
limit
dilut
assay
veronk
cell
monolay
growth
curv
recombin
parent
virus
determin
veronk
cell
infect
moi
describ
combredet
et
al
indirect
immunofluoresc
assay
monolay
veronk
cell
plate
mm
glass
coverslip
plate
infect
recombin
mvschwsar
parent
mvschw
virus
multipl
infect
moi
syncytia
clearli
visibl
yet
confluent
h
infect
cell
wash
dpb
fix
paraformaldehyd
min
instanc
permeabil
triton
min
coverslip
incub
min
antissol
hyperimmun
mous
ascit
fluid
dilut
donkey
serum
dk
subsequ
incub
antimous
igg
secondari
antibodi
jackson
immunoresearch
sampl
mount
slide
dapicontain
vectashield
vector
laboratori
analyz
axioplan
epifluoresc
microscop
zeiss
pictur
acquir
axiocam
mrm
camera
process
axiovis
softwar
v
zeiss
western
blot
assay
cytosol
cell
extract
prepar
veronk
cell
infect
recombin
mvschwsar
parent
mvschw
virus
essenti
describ
previous
lorin
et
al
protein
separ
sdspolyacrylamid
gel
transfer
onto
pvdf
membran
prior
immunoblot
rabbit
anti
antibodi
describ
callendret
et
al
experi
approv
conduct
accord
pasteur
institut
guidelin
complianc
european
anim
welfar
regul
obtain
mice
permiss
measl
vaccin
mrkic
et
al
fvb
mice
heterozyg
measl
vaccin
receptor
transgen
backcross
mice
lack
type
ifn
combredet
et
al
gener
backcross
breed
coloni
result
line
acquir
uniform
background
sixto
nineweekold
mice
use
assess
immun
respons
induc
recombin
mvschwsar
group
mice
inject
intraperiton
ip
tcid
recombin
mvschwsar
parent
mvschw
control
group
mice
inject
intramuscularli
formul
contain
mg
purifi
ssol
polypeptid
mg
aluminum
hydroxid
alugel
serva
booster
inject
administ
week
thereaft
serum
sampl
collect
one
week
immun
week
inject
pi
sera
measur
induct
sarscov
specif
antibodi
immun
mice
indirect
elisa
neutral
assay
describ
previous
callendret
et
al
briefli
microtit
plate
coat
sarscov
infect
mockinfect
crude
cell
lysat
incub
serial
dilut
test
sera
bound
antibodi
reveal
mousespecif
antiigg
amersham
secondari
antibodi
coupl
horseradish
peroxidas
tmb
tetramethylbenzidin
kpl
read
well
coat
mock
lysat
substract
well
sarscov
lysat
sarscov
specif
igg
titer
calcul
reciproc
highest
dilut
individu
serum
give
absorb
isotyp
determin
antibodi
respons
perform
use
isotypespecif
secondari
antibodi
coupl
horseradish
peroxidas
southern
biotech
iga
titer
similarli
measur
use
mousespecif
antiiga
secondari
antibodi
southern
biotech
calcul
reciproc
highest
dilut
individu
serum
give
absorb
mv
specif
antibodi
similarli
measur
use
elisa
plate
coat
purifi
measl
antigen
triniti
biotech
usa
neutral
twofold
serial
dilut
heatinactiv
serum
sampl
incub
min
sarscov
ad
subconflu
monolay
cell
microtit
plate
dilut
serum
test
quadrupl
cytopath
effect
cpe
endpoint
read
day
inocul
neutral
antibodi
titer
determin
accord
reed
muench
method
reed
muench
reciproc
highest
dilut
serum
suppress
cpe
least
well
five
week
second
immun
anim
lightli
anesthet
isofluran
mundipharma
inocul
intranas
pfu
sarscov
ml
pb
mice
euthan
h
challeng
infect
lung
homogen
prepar
ml
dmem
supplement
fc
titrat
infecti
viru
monolay
describ
callendret
et
al
viral
rna
extract
use
qiaamp
viral
rna
mini
kit
qiagen
ml
tissu
homogen
accord
manufactur
recommend
elut
ml
rnasefre
water
analyz
realtim
rtpcr
describ
challeng
infect
anim
subsequ
analysi
involv
infecti
materi
done
jean
merieux
biosafeti
level
contain
laboratori
statist
analysi
perform
log
viral
titer
measur
individu
mice
use
student
independ
ttest
assumpt
use
small
sampl
normal
distribut
variabl
varianc
popul
compar
sarscov
genom
rna
level
tissu
rna
sampl
quantifi
realtim
rtpcr
prism
sequenc
detect
system
briefli
rna
sampl
ml
reversetranscrib
amplifi
taqman
one
step
pcr
master
mix
reagent
kit
appli
biosystem
accord
manufactur
recommend
combin
primer
set
flurorogen
probe
specif
nucleoprotein
n
gene
drosten
et
al
reaction
perform
thermofast
reaction
plate
abgen
ml
mixtur
contain
ml
templat
rna
nm
concentr
primer
tggacccac
agattcaac
gctgtgaac
caagacgca
eurogentec
nm
concentr
probe
eurogentec
cycl
condit
min
follow
min
cycl
fluoresc
read
combin
annealingextens
step
absolut
quantif
rna
done
use
vitro
transcrib
rna
standard
prepar
clone
sarscov
n
gene
quantifi
spectrophotometr
analyt
sensit
realtim
n
rtpcr
assay
experiment
determin
use
limit
serial
dilut
n
rna
standard
use
probit
nonlinear
regress
analysi
detect
limit
rtpcr
calcul
copi
input
rna
per
reaction
correspond
log
viru
genomeequival
geq
per
mous
tissu
assum
effici
rna
prepar
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
